NASDAQ
GRFS

Grifols SA ADR

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Grifols SA ADR Stock Price

Vitals

Today's Low:
$9.46
Today's High:
$9.785
Open Price:
$9.46
52W Low:
$5.71
52W High:
$10.97
Prev. Close:
$9.19
Volume:
371431

Company Statistics

Market Cap.:
$8.04 billion
Book Value:
4.3185
Revenue TTM:
$6.48 billion
Operating Margin TTM:
9.47%
Gross Profit TTM:
$2.23 billion
Profit Margin:
0.13%
Return on Assets TTM:
1.81%
Return on Equity TTM:
1.24%

Company Profile

Grifols SA ADR had its IPO on 2006-05-17 under the ticker symbol GRFS.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Grifols SA ADR has a staff strength of 23,631 employees.

Stock update

Shares of Grifols SA ADR opened at $9.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.46 - $9.79, and closed at $9.7.

This is a +5.55% increase from the previous day's closing price.

A total volume of 371,431 shares were traded at the close of the day’s session.

In the last one week, shares of Grifols SA ADR have increased by +3.3%.

Grifols SA ADR's Key Ratios

Grifols SA ADR has a market cap of $8.04 billion, indicating a price to book ratio of 0.7986 and a price to sales ratio of 1.2683.

In the last 12-months Grifols SA ADR’s revenue was $6.48 billion with a gross profit of $2.23 billion and an EBITDA of $921.07 million. The EBITDA ratio measures Grifols SA ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Grifols SA ADR’s operating margin was 9.47% while its return on assets stood at 1.81% with a return of equity of 1.24%.

In Q2, Grifols SA ADR’s quarterly earnings growth was a negative -38.5% while revenue growth was a positive 7.8%.

Grifols SA ADR’s PE and PEG Ratio

Forward PE
13.2802
Trailing PE
48.3684
PEG
0.4093

Its diluted EPS in the last 12-months stands at $0.19 per share while it has a forward price to earnings multiple of 13.2802 and a PEG multiple of 0.4093. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Grifols SA ADR’s profitability.

Grifols SA ADR stock is trading at a EV to sales ratio of 3.0855 and a EV to EBITDA ratio of 17.442. Its price to sales ratio in the trailing 12-months stood at 1.2683.

Grifols SA ADR stock pays annual dividends of $0 per share, indicating a yield of 7.09% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$21.43 billion
Total Liabilities
$1.88 billion
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Grifols SA ADR ended 2024 with $21.43 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $21.43 billion while shareholder equity stood at $5.86 billion.

Grifols SA ADR ended 2024 with $0 in deferred long-term liabilities, $1.88 billion in other current liabilities, 1030332000.00 in common stock, $-56221000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $523.35 million and cash and short-term investments were $557.24 million. The company’s total short-term debt was $733,269,000 while long-term debt stood at $0.

Grifols SA ADR’s total current assets stands at $4.80 billion while long-term investments were $2.54 billion and short-term investments were $33.88 million. Its net receivables were $865.71 million compared to accounts payable of $0 and inventory worth $3.32 billion.

In 2024, Grifols SA ADR's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Grifols SA ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$9.7
52-Week High
$10.97
52-Week Low
$5.71
Analyst Target Price
$10.94

Grifols SA ADR stock is currently trading at $9.7 per share. It touched a 52-week high of $10.97 and a 52-week low of $10.97. Analysts tracking the stock have a 12-month average target price of $10.94.

Its 50-day moving average was $9.84 and 200-day moving average was $8.76 The short ratio stood at 4.8 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 4627.6% are held by institutions.

Frequently Asked Questions About Grifols SA ADR

The stock symbol (also called stock or share ticker) of Grifols SA ADR is GRFS

The IPO of Grifols SA ADR took place on 2006-05-17

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$245.73
-7.41
-2.93%
$69
-2
-2.82%
$41.7
-0.7
-1.65%
$70.11
-3.64
-4.94%
$30.63
-0.2
-0.65%
$1870.8
7.9
+0.42%
$149.1
-9.6
-6.05%
$84.45
-0.08
-0.09%
$115.2
-3.4
-2.87%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Address

Avinguda de la Generalitat, 152, Barcelona, Spain, 08174